Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Receivables - Other: 2020-2021

  • SAB Biotherapeutics' Receivables - Other changed negligibly% to $6,250 in Q4 2021 from the same period last year, while for Dec 2021 it was $6,250, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $6,250 for FY2021, which is negligibly% changed negligibly from last year.
  • As of Q4 2021, SAB Biotherapeutics' Receivables - Other stood at $6,250, which was down 0.00% from $6,250 recorded in Q4 2020.
  • In the past 5 years, SAB Biotherapeutics' Receivables - Other registered a high of $6,250 during Q4 2020, and its lowest value of $6,250 during Q4 2020.
  • Over the past 2 years, SAB Biotherapeutics' median Receivables - Other value was $6,250 (recorded in 2021), while the average stood at $6,250.